Please assess the completion status of the following clinical trial:

Trial Title: The EndoGastric Solutions TEMPO Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years;~2. GERD for \> 1 year;~3. History of daily PPIs for \> 6 months;~4. At least daily bothersome medically refractory GERD symptom(s) other than heartburn on PPIs;~5. Hill grade I and II at gastroesophageal junction;~6. Proven gastroesophageal reflux by either endoscopy, ambulatory pH or barium swallow testing;~7. Willingness to undergo pH testing;~8. Willingness to cooperate with the postoperative diet;~9. Availability for follow-up visits at 6, 12, 24, and 36 months;~10. Willingly and cognitively signed inform consent~Exclusion Criteria:~1. BMI \> 35 Hiatal hernia \> 2c m in axial height and \> 2 cm in greatest transverse dimension;~2. Esophagitis grade C and D;~3. Barrett's esophagus \> 2 cm;~4. Esophageal ulcer;~5. Fixed esophageal stricture or narrowing;~6. Portal hypertension and/or varices;~7. Active gastro-duodenal ulcer disease; Gastric outlet obstruction or stenosis;~8. Gastroparesis;~9. Coagulation disorders;~10. History of any of the following: resective gastric or esophageal surgery, antireflux surgery with anatomy unsuitable for TIF procedure per physician judgment, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis;~11. Pregnancy or plans of pregnancy in the next 12 months;~12. Enrollment in another device or drug study that may confound the results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
- Control (Type: ACTIVE_COMPARATOR): Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).